Breaking News, Trials & Filings

Peregrine Antibody Shows Combo Benefit in Preclinical Model

Combination with anti-CTLA-4 antibody yields positive results in mouse melanoma

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Peregrine Pharmaceuticals will present data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting showing that phosphatidylserine (PS)-targeting antibodies reactivate tumor immunity at multiple levels and that these antibodies, when combined with an anti-CTLA-4 antibody yielded enhanced anti-tumor activity in a preclinical model of melanoma. Peregrine is planning to start a Phase III trial in second-line non-small cell lung cancer (NSCLC) with its lead PS-targeting antibody bavituxima...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters